Problems of high-dose methotrexatein oncological patients

Monahan BP, Allegra CJ. Antifolates. In: Chabner BA, Longo DL, editors. Cancer chemotherapy & biotherapy: principles & practices, 4th ed. New York: Lippincott Williams & Wilkins, 2006: 92-124.Search in Google Scholar

Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. Antineoplastic agents. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill Medical Publishing Division, 2001: 1399-1404.Search in Google Scholar

Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996; 42; 8(B): 1322-1329.10.1093/clinchem/42.8.1322Search in Google Scholar

DeVita VT, Jr, Hellman S, Rosenberg SA. Cancer: principles & practice of oncology, 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005.Search in Google Scholar

Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Colorado, 2006.Search in Google Scholar

Crom WR, Pratt CB, Green AA, Champion JE, Crom DB, Stewart CF et al. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. J Clin Oncol 1984; 2: 655-661.10.1200/JCO.1984.2.6.655Search in Google Scholar

Josting A, Diehl V, Engert A. Methotrexat: Pharmakologie, Toxizität und Rescue-massnahmen bei hochdosier ter Behandlung. Onkologe 1998; 4: 974-985.10.1007/s007610050286Search in Google Scholar

Solimando DA. Drug information handbook for oncology, 5th ed. Drug Information Series, Lexi-Comp. Inc, 2005.Search in Google Scholar

British Naional Formulary 55, BMJ Group and RPS Publishing, 2008.Search in Google Scholar

Bleyr WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978; 41: 36-51.10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-ISearch in Google Scholar

Cova D, Lorusso V, Silvestris N. The pharmacokinetics and pharmacodynamics of drugs in elderly cachectic (cancer) patients. In: Mantovani G. Cachexia and Wasting: A Modern Approach. Springer Milan, 2006: 377-382.Search in Google Scholar

Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of snticancer agents. Nat Rev Cancer 2005; 5:447-458.10.1038/nrc1629Search in Google Scholar

Fleming RF, Eldridge RM, Johnson CE, Stewart CF. Disposition of high-dose methotrexate in an obese cancer patient. Cancer 1991; 68: 1247-1250.10.1002/1097-0142(19910915)68:6<1247::AID-CNCR2820680611>3.0.CO;2-OSearch in Google Scholar

Abdah-Bortnyak R, Tsalic M, Haim N. Actual body weight for determining doses of chemotherapy in obese cancer patients. Med Oncol 2003; 20: 363-367.10.1385/MO:20:4:363Search in Google Scholar

Jaehde U, Kloft C. Dosis-Individualisierung in der Krebs-Chemotherapie. Pharm Unserer Zeit 2006; 2: 150-156.10.1002/pauz.200500164Search in Google Scholar

Skaerby T, Joensson P, Hjorth L, Behrentz M, Bjoerk O, Forestier E et al. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother and Pharmacol 2003; 51: 311-320.10.1007/s00280-002-0552-1Search in Google Scholar

Bauters TGM, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sc 2008; 30(3).10.1007/s11096-008-9204-9Search in Google Scholar

Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother 2000; 34: 1024-1027.10.1345/aph.1909410981249Search in Google Scholar

Hon ZZ, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998; 44: 388-400.Search in Google Scholar

Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11: 694-703.10.1634/theoncologist.11-6-69416794248Search in Google Scholar

Esteve MA, Devictor-Pierre B, Galy G, Andre N, Coze C, Lacarelle B et al. Severe acute toxicity assiciated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation. Eur J Clin Pharmacol 2007; 63: 39-42.10.1007/s00228-006-0212-117115148Search in Google Scholar